Key Highlights

  • Bone Biologics (NASDAQ:BBLG) reported a third quarter 2026 net loss of USD 617,651, or USD 0.17 per share, against a published consensus loss of USD 0.19, and a nine month net loss of USD 2.16 million.
  • Cash was USD 6.09 million at September 30, 2026, up from USD 5.33 million at year end 2025, and management expects it to fund operations through the second quarter of 2027.
  • The company raised USD 2.64 million in net proceeds from a July 2026 private placement of 2,112,677 units priced at USD 1.419 and has 534,000 pre-funded warrants outstanding.
  • The quarterly report states that substantial doubt exists about the company's ability to continue as a going concern, with operating spending estimated at USD 6.0 million over the next twelve months.

What Bone Biologics Reported

Bone Biologics reported results for the quarter ended September 30, 2026, and the earnings board lists the report on October 26, 2026. The net loss was USD 617,651, or USD 0.17 per share, against the published consensus loss of USD 0.19, so the loss was USD 0.02 smaller, simple arithmetic on two published numbers. For the nine months the net loss was USD 2,157,341, or USD 0.88 per share. Cash was USD 6,088,085, with about USD 5.9 million held in a flexible certificate of deposit at Bank of America. The company is a clinical stage medical device developer with no product revenue, so results mainly reflect research spending and financing.

NELL-1 Trial and Regulatory Path

Bone Biologics develops NB1, which combines the bone growth protein NELL-1 with demineralized bone matrix for spinal fusion. A multicenter pilot study of up to 30 adults with degenerative disc disease undergoing transforaminal lumbar interbody fusion is under way in Australia. The FDA Division of Orthopedic Devices agreed to the study design in a pre-submission, supporting progress toward a pivotal trial in the United States, and the agency indicated that NELL-1 with demineralized bone matrix will be a device and drug combination product requiring a premarket approval application before commercial sale. That is a lengthy and costly route, which explains the repeated need for financing. A pilot study in Australia can generate safety and performance data for regulators, though it is smaller than a pivotal trial.

Funding, Going Concern and What to Watch

Management estimates operating spending of USD 6.0 million over the next twelve months against cash of USD 6.09 million, simple arithmetic that leaves little cushion, and the filing states that conditions raise substantial doubt about continuing as a going concern. Until July 24, 2027 the company may not enter variable-rate financings apart from at-the-market sales through Wainwright. New equity would dilute holders of Bone Biologics (NASDAQ:BBLG). Investors can watch enrolment in the Australian pilot, any update on the FDA pivotal trial plan, and the timing and terms of further financing, since results from an early pilot study may not predict later outcomes. Any extension of the runway beyond mid-2027 will probably need new capital.

Where Things Stand

Cash of USD 6.09 million is expected to fund operations through the second quarter of 2027, about three quarters from now, so the answer is that the runway is short and the filing carries a going concern warning. The quarterly loss of USD 0.17 per share beat the USD 0.19 expected. For Bone Biologics (NASDAQ:BBLG) the key tests are progress in the Australian pilot and the ability to raise more capital on acceptable terms. The company must raise capital before mid-2027 unless costs fall.